DIVIS LABORATORIES LTD - Q1 FY 21 RESULTS REVIEW - DATED 22 09 2020

 

DIVIS LABORATORIES

Q1 FY 21 RESULTS REVIEW

DATED 22 09 2020

 

COMPANY OVERVIEW                       

                          

Divis Laboratories Ltd is engaged in the manufacture of Active Pharma Ingredients (APIs) and intermediates. The company in a matter of short time expanded their breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

They are actively involved in developing alternate, patent non-infringing processes for APIs, for the inventors to manage late life cycle and leading generic drug manufacturers.

The company`s product range includes Bupropion Hbr,Bupropion HCL, Capecitabine, Carbidopa, Desloratadine, Dexlansoprazole /(R)-Lansoprazole, Irbesartan, Levodopa, Niacin, Sibutramine HCL, Valacyclovir HCL, Valsartan, Venlafaxine HCL, VerapamiL HCL, ETC                     

Management                   

Ramesh B V Nimmagadda  Non Executive Chairman   

Murali K Divi               Managing Director      

 

QUARTERLY RESULTS :

Divis Laboratories (in Rs. Cr.)	Jun '20	Mar '20	Dec '19	Sep '19	Jun '19	YOY	QOQ
Net Sales	1,730.47	1,389.71	1,396.26	1,445.57	1,162.88	48.81	24.52
Consumption of Raw Materials	464.27	545.68	529.95	612.86	509.92	-8.95	-14.92
Purchase of Traded Goods	3.79	9.93	3.11	1.84	1.23	208.13	-61.83
Increase/Decrease in Stocks	171.78	-40.2	14.08	-21.04	-58.82	-392.04	-527.31
Employees Cost	183.9	173.14	156.48	150.57	140.86	30.56	6.21
Depreciation	56.2	49.78	46.7	45.93	43.83	28.22	12.9
Other Expenses	206.65	256.71	198.74	210.78	182.55	13.2	-19.5
P/L Before Other Inc., Int., Excpt. Items & Tax	643.88	394.67	447.2	444.63	343.31	87.55	63.14
Other Income	17.33	76.73	41.67	47.03	30.32	-42.84	-77.41
P/L Before Int., Excpt. Items & Tax	661.21	471.4	488.87	491.66	373.63	76.97	40.27
Interest	0.23	0.44	1.55	3.79	0.32	-28.13	-47.73
P/L Before Tax	660.98	470.96	487.32	487.87	373.31	77.06	40.35
Tax	168.92	82.73	128.23	131.09	100.87	67.46	104.18
Net Profit	492.06	388.23	359.09	356.78	272.44	80.61	26.74
Equity Share Capital	53.09	53.09	53.09	53.09	53.09	0	0
Basic EPS	18.54	14.62	13.53	13.44	10.26	80.7	26.81
MP	3245
PE	43.75674	TOO HIGH
VOLUMES	10,64,745
Market Depth
BUY 241.00
SELL 580.00
52 Wk L/H	1571.25	3388

 

 

Annual Results	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Sales	5,394	4,946	3,891	4,064	3,776
Other Income	189	155	113	74	97
Total Income	5,584	5,101	4,004	4,139	3,873
Total Expenditure	3,758	3,243	2,772	2,741	2,477
EBIT	1,825	1,858	1,232	1,397	1,396
Interest	6	3	1	2	3
Tax	442	502	354	334	267
Net Profit	1,376	1,352	877	1,060	1,125

 

Historical Prices
	3YR BEF	Current Price	%Gain / Loss
Open Price	874	3240	270.71
	2YR BEF
Open Price	1370.4	3240	136.43
	1YR BEF
Open Price	1616	3240	100.5
	3M BEF
Open Price	2329.8	3240	39.07

 

Share Holding Pattern in (%)
Standalone	Jun-20	Mar-20	Dec-19	Sep-19
Promoters	51.97	51.97	52	52.01
Pledged	0	0	0	0
FII/FPI	18.17	19.08	19.7	19.61
Total DII	21.28	20.39	20.1	20.3
Fin.Insts	1.23	0.93	0.59	0.26
Insurance Co	0	0	0	0
MF	15.57	14.67	14.89	15.21
Others DIIs	4.48	4.79	4.62	4.83
Others	8.59	8.57	8.21	8.09
Total	100.01	100.01	100.01	100.01

 

 

CHARTS

Apr-2020       LOWEST PRICE POINT

AFTERWARDS      UPWARD CURVE

      

MONTHLYTECHNICAL RATING    

Very Bullish  

Valuation 

Market Cap (Rs Cr.)    88,857.64    

P/E                            55.57    

Book Value (Rs)          275.61  

Dividend (%)              800

Industry P/E                37.25    

EPS (TTM)                   60.18    

P/C                             49.78    

Price/Book                  12.14    

Dividend Yield.(%)      0.48      

Face Value (RS)          2    

 

Per Share Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Basic EPS (Rs.)	52	51	33	40	42
Diluted Eps (Rs.)	52	51	33	40	42
Book Value [Excl. Reval Reserve]/Share (Rs.)	275	262	223	202	162
Dividend/Share (Rs.)	16	16	10	10	10
Face Value	2	2	2	2	2
Margin Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Gross Profit Margin (%)	37	41	35	37	40
Operating Margin (%)	34	38	32	34	37
Net Profit Margin (%)	26	27	23	26	30
Return Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Return on Networth / Equity (%)	19	19	15	20	26
ROCE (%)	24	26	20	25	26
Return On Assets (%)	16	17	13	17	23
Leverage Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
Debt to Equity (x)	0	0	0	0	0
Interest Coverage Ratios (%)	299	531	927	621	369
aluation Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
P/E (x)	4	6	8	7	5
P/B (x)	7	7	5	3	6
EV/EBITDA (x)	26	22	21	11	17
P/S (x)	10	9	7	4	7
Growth Ratios	Mar-20	Mar-19	Mar-18	Mar-17	Mar-16
3 Yr CAGR Sales (%)	18	10	1	14	22
3 Yr CAGR Net Profit (%)	26	12	-11	12	18